Int J Med Sci 2020; 17(13):1992-2001. doi:10.7150/ijms.44723
MiR-145 functions as a tumor suppressor in Papillary Thyroid Cancer by inhibiting RAB5C
1. Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
2. Department of Otolaryngology head and neck surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Zhang W, Ji W, Li T, Liu T, Zhao X. MiR-145 functions as a tumor suppressor in Papillary Thyroid Cancer by inhibiting RAB5C. Int J Med Sci 2020; 17(13):1992-2001. doi:10.7150/ijms.44723. Available from https://www.medsci.org/v17p1992.htm
Papillary thyroid carcinoma (PTC) accounts for the largest proportion of thyroid cancers; and its morbidity rate has dramatically increased in recent decades. However, the pathogenesis mechanisms of PTC are still not clear. This study aimed to reveal that miR-145 acts as an antitumor miRNA in the progression of PTC. In the present study, the expression of miR-145 was analyzed in 57 paired PTC patient samples. The relationship between clinicopathological features and miR-145 expression were also defined. The tumor suppressive function of miR-145 on PTC cell metastasis, proliferation and apoptosis were revealed in vitro. Also, we used dual luciferase reporter assay to define the relationship of miR-145 and RAB5C. RAB5C was reported to participate in cell invasion and cell motility. We found that miR-145 was downregulated in PTCs, which was negatively correlated with PTC progression and metastasis. MiR-145 inhibited PTC migration, proliferation and promoted apoptosis by directly suppresing RAB5C. In conclusion, miR-145 functions as a tumor suppressor in PTC by inhibiting RAB5C. MiR-145 and RAB5C are potential therapeutic targets in therapy of aggressive PTC cases.
Keywords: miR-145, RAB5C, papillary thyroid carcinoma, PTC